drugset / Trial / NCT02513329
Stellate Ganglion Block (SGB) For Women for Breast Cancer
RandomizedParallel-groupSingle-blindSupportive care
Summary
Vasomotor symptoms (VMS) affect up to 65% of breast cancer survivors and negatively impact their quality of life. The investigators aim to evaluate the benefit of SGB in symptomatic women with breast cancer who are on anti-estrogens and are seeking relief from moderate to very severe VMS that are adversely affecting health and wellbeing. Women with breast cancer on Tamoxifen, aromatase inhibitors (AIs) or Selective Estrogen Receptor Modulators (SERMS) with moderate to very severe VMS will be enrolled as participants in this study.
Timeline
- Start
- 2015-07
- Primary completion
- 2020-01
- Completion
- 2020-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Bupivicaine | Other / unclassified | 10 ml | Other |